To this end, we planned the RACTAC (Repurposing the Antipsychotic drug Chlorpromazine as a Therapeutic Agent in the Combined treatment of newly diagnosed glioblastoma) phase II multicenter, single-arm study, in which CPZ is added to adjuvant TMZ in the first-line therapy of GBM patients whose tumor is characterized by an unmethylated MGMT gene promoter (8). The gene discussed is MGMT; the disease is glioblastoma.